FDA NDC Directory · JSON-LD · Markdown

Skyrizi

NDC 0074-8300 · HUMAN PRESCRIPTION DRUG · INJECTION

Generic namerisankizumab-rzaa
Labeler / ManufacturerAbbVie Inc.
Marketing categoryBiologic License Application · App BLA761105
Dosage form / routeINJECTION · SUBCUTANEOUS
Active ingredientsRISANKIZUMAB (180 mg/1.2mL)
Marketing started20250903
Package count1

External sources

Source: openFDA. Public-domain (CC0).